

SYNTHESIS OF ADENINE 7-OXIDE FROM ADENINE: UTILIZATION OF A BENZYL GROUP AS A CONTROL SYNTHON AT THE 3-POSITION

Tozo Fujii,* Kazuo Ogawa, Tohru Saito, Keiko Kobayashi, and Taisuke Itaya

Faculty of Pharmaceutical Sciences, Kanazawa University, Takaramachi, Kanazawa 920, Japan

Abstract—The first unequivocal synthetic route to adenine 7-oxide (**7**) has been established. The route started with peroxy-carboxylic acid oxidation of 3-benzyladenine (**5**), readily obtainable from adenine (**2**) by benzylation, and proceeded through nonreductive debenylation of the resulting 3-benzyladenine 7-oxide (**6**).

Adenine (**2**) undergoes *N*-oxidation preferentially at the 1-position, when treated with 30% aqueous H₂O₂ in AcOH at room temperature.¹ This regioselectivity appears to reflect the generalization² that on *N*-oxidation pyrimidine compounds form only mono-*N*-oxides, whereas imidazoles are resistant to *N*-oxidation. On the other hand, Rhaese³ claimed that adenine 7-oxide (**7**) was obtained from **2** in 5% yield by treating it with 0.1 M H₂O₂ in 0.01 M phosphate buffer (pH 7.0) at 37°C for 5 days and that **7** was among the products from X-ray irradiation of **2** in 0.05 M phosphate buffer (pH 7.0). These results were reportedly reproduced by Yamamoto.⁴ However, the chemical and spectroscopic evidence adduced by both authors appeared too incomplete to assign the N(7)-oxide structure to their samples which they thought to be **7**, and we completely failed to obtain any *N*-oxides from **2** on repetition of the H₂O₂/buffer oxidation procedure³ of Rhaese. This led us to devise a three-step route for the synthesis of adenine 7-oxide (**7**) from adenine (**2**) in the present work.

The direct alkylation of **2** at the 3-position in the absence of added base presents the most convenient method of securing 3-alkyladenines (type **5**),⁵ and the second stage of alkylation of the 3-substituted adenines (type **5**) provides a ready access to 3,7-disubstituted adenines (type **1**).^{5,6} If there would be a parallelism between *N*-alkylation and *N*-oxidation in regioselectivity at the second stage and if a similar two-step reaction sequence involving *N*-oxidation would be coupled with removal of the 3-substituent, it should conclude a synthesis of adenine 7-oxide (**7**). This has now been realized by the use of the benzyl group at the 3-position (Scheme 1).

Treatment of 3-benzyladenine (**5**), obtainable from **2** in 53% yield according to the literature procedure,⁵ with magnesium monoperoxyphthalate hexahydrate (MMPP·6H₂O)⁷ in MeOH at 30°C for 20 h furnished the N(7)-oxide (**6**) in the form of the monohydrate (6·H₂O) [mp 262–265°C (decomp.)]^{8,9} in 40% yield, together with 51% recovery of **5**. Replacement of MMPP·6H₂O by *m*-chloroperoxybenzoic acid (MCPBA) [in MeOH–1 M

On catalytic reduction (Raney Ni/H₂, H₂O, 1 atm, 50°C, 4 h), **7** produced adenine (**2**) in 92% yield. Treatment of **7** with boiling AcOH for 5 h gave, after recrystallization of the product from 5% aqueous H₂SO₄, 8-oxoadenine sulfate (**3**·1/2H₂SO₄)¹⁵ in 69% yield. The apparent migration of the oxygen function from N(7) to C(8) under acidic conditions is analogous to that observed for guanine 7-oxide¹⁶ and hypoxanthine 7-oxide (**8**).^{11d} Deamination of **7** with NaNO₂ in aqueous HCl at 90°C provided hypoxanthine 7-oxide (**8**)^{11d} and its N(7)→C(8) O-migration product (**4**)^{11d} in 4% and 45% yields, respectively.

In addition, methylation of **7** with MeI in AcNMe₂ at 25°C for 20 h gave 3-methyladenine 7-oxide dihydrate (**10**·2H₂O) [mp 255–265°C (decomp.)]¹⁷ in 25% yield and 7-methoxy-3-methyladenine (**12**), which was isolated in 17% yield in the form of the perchlorate salt (**12**·HClO₄) [mp 251–253°C (decomp.)].¹⁸ A similar methylation (25°C, 18 h) converted **10**·2H₂O into **12**·HClO₄ in 89% yield. The uv spectrum of **12**·HClO₄ was similar to those^{6a} of 3,7-dialkyladenine salts. On catalytic reduction (Raney Ni/H₂, H₂O, 1 atm, 40°C, 4 h), **10**·2H₂O and **12**·HClO₄ separately produced 3-methyladenine (**11**) in 90% and 73% yields, respectively. On the other hand, treatment of **7** with dimethyl sulfate in 1 N aqueous NaOH at room temperature for 1 h gave **10**·2H₂O and 7-methoxyadenine (**9**) (mp > 300°C)¹⁹ in 23% and 22% yields, respectively. Catalytic hydrogenation (Raney Ni/H₂, H₂O, 1 atm, 40°C, 4 h) of **9** provided adenine (**2**) in 81% yield.

In summary, the above results have established a three-step synthetic route to adenine 7-oxide (**7**) from adenine (**2**) via 3-benzyladenine (**5**) and 3-benzyladenine 7-oxide (**6**). The use of the readily removable benzyl group at the 3-position of **2** as a directing group for alteration of regioselectivity in N-oxidation has furnished a firm basis for the present successful synthesis of **7**. The location of the oxygen function in **6** and **7** has also been confirmed by preliminary X-ray crystallographic analysis.²⁰ Since the chemical, chromatographic, and spectroscopic data obtained with our synthetic **7** do not accord with the literature,^{3,4} it is hoped that this communication will serve as the first and valid report dealing with the synthesis and characterization of adenine 7-oxide.

ACKNOWLEDGMENT

The authors are grateful to Messrs. Kado Ikeda, Katsuhiko Ikeda, and Fujio Nohara, Ikeda Mohando Co., Ltd., for their interest and encouragement.

REFERENCES AND NOTES

1. (a) M. A. Stevens, D. I. Magrath, H. W. Smith, and G. B. Brown, *J. Am. Chem. Soc.*, 1958, **80**, 2755; (b) M. A. Stevens and G. B. Brown, *ibid.*, 1958, **80**, 2759; (c) T. Fujii and T. Itaya, *Tetrahedron*, 1971, **27**, 351; (d) T. Fujii, T. Saito, K. Kizu, H. Hayashibara, Y. Kumazawa, S. Nakajima, and T. Fujisawa, *Chem. Pharm. Bull.*, 1991, **39**, 301.
2. E. Ochiai, 'Aromatic Amine Oxides,' Elsevier, Amsterdam, 1967, pp. 50–51.
3. H.-J. Rhaese, *Biochim. Biophys. Acta*, 1968, **166**, 311.
4. O. Yamamoto, *J. Radiat. Res.*, 1980, **21**, 239.
5. T. Fujii, G. C. Walker, N. J. Leonard, D. C. DeLong, and K. Gerzon, *J. Med. Chem.*, 1979, **22**, 125, and references cited therein.

6. (a) T. Fujii, T. Saito, I. Inoue, Y. Kumazawa, and N. J. Leonard, *Chem. Pharm. Bull.*, 1986, **34**, 1821; (b) N. J. Leonard, T. Fujii, and T. Saito, *ibid.*, 1986, **34**, 2037.
7. P. Brougham, M. S. Cooper, D. A. Cummerson, H. Heaney, and N. Thompson, *Synthesis*, 1987, 1015.
8. Satisfactory analytical and spectroscopic data have been obtained for all of the new compounds reported herein.
9. Selected spectral data for **6**•H₂O: ms *m/z*: 241 (M⁺); uv λ_{max} [95% (v/v) aq. EtOH] 265 nm (ε 12200), 322 (2200); λ_{max} [H₂O (pH 1)] 280 (14700); λ_{max} [H₂O (pH 7)] 262 (12300), 307 (4000); λ_{max} [H₂O (pH 13)] 265 (10700), 296 (sh) (5800); ¹H nmr (Me₂SO-*d*₆) δ: 5.46 (2H, s, CH₂Ph), 7.27–7.40 and 7.42–7.48 (5H, m, CH₂Ph), 7.97 [1H, s, C(8)-H], 8.09 and 8.91 (1H each, br, NH's), 8.70 [1H, s, C(2)-H]. The assignments of the C(2)-H and C(8)-H signals have been made by comparison with those of the 2-deuterated species.
10. (a) G. B. Payne, P. H. Deming, and P. H. Williams, *J. Org. Chem.*, 1961, **26**, 659; (b) G. B. Payne, *ibid.*, 1961, **26**, 668.
11. (a) L. M. Weinstock, R. J. Tull, A. W. Douglas, and I. Shinkai, *J. Org. Chem.*, 1980, **45**, 5419; (b) K. Ogawa, M. Nishii, J. Inagaki, F. Nohara, T. Saito, T. Itaya, and T. Fujii, *Chem. Pharm. Bull.*, 1992, **40**, 343; (c) *Idem, ibid.*, 1992, **40**, 1315; (d) K. Ogawa, M. Nishii, F. Nohara, T. Saito, T. Itaya, and T. Fujii, *ibid.*, 1992, **40**, 612.
12. Selected spectral data for **7**: ms *m/z*: 151 (M⁺); uv λ_{max} [95% (v/v) aq. EtOH] 246 nm (sh) (ε 5400), 271 (9100); λ_{max} [H₂O (pH 1)] 274 (11500); λ_{max} [H₂O (pH 7)] 235 (12400), 284 (6100); λ_{max} [H₂O (pH 13)] 235 (13000), 285 (6200); ¹H nmr (Me₂SO-*d*₆) δ: 7.01 (2H, dull s, NH₂), 8.17 [1H, s, C(2)-H], 8.35 [1H, s, C(8)-H], 12.0–13.0 (1H, br, NH); ¹H nmr (D₂O) δ: 8.26 [1H, s, C(2)-H], 8.29 [1H, s, C(8)-H]. The assignments of the C(2)-H and C(8)-H signals have been made by comparison with those of the 2-deuterated species.
13. I. Scheinfeld, J. C. Parham, S. Murphy, and G. B. Brown, *J. Org. Chem.*, 1969, **34**, 2153.
14. A. A. Watson, *J. Org. Chem.*, 1977, **42**, 1610.
15. T. Fujii and T. Saito, *Chem. Pharm. Bull.*, 1973, **21**, 1954.
16. M. Nishii, J. Inagaki, F. Nohara, K. Isono, H. Kusakabe, K. Kobayashi, T. Sakurai, S. Koshimura, S. K. Sethi, and J. A. McCloskey, *J. Antibiot.*, 1985, **38**, 1440.
17. Selected spectral data for **10**•2H₂O: ms *m/z*: 165 (M⁺); uv λ_{max} [95% (v/v) aq. EtOH] 263 nm (ε 13100), 316 (3200); λ_{max} [H₂O (pH 1)] 278 (14400); λ_{max} [H₂O (pH 7)] 259 (12100), 303 (4100); λ_{max} [H₂O (pH 13)] 262 (11000), 295 (sh) (5400); ¹H nmr (Me₂SO-*d*₆) δ: 3.81 [3H, s, N(3)-Me], 7.90 [1H, s, C(8)-H], 8.05 and 8.69 (1H each, br, NH's), 8.38 [1H, s, C(2)-H].
18. Selected spectral data for **12**•HClO₄: uv λ_{max} [95% (v/v) aq. EtOH] 281 nm (ε 16200); λ_{max} [H₂O (pH 1)] 278 (15600); λ_{max} [H₂O (pH 7)] 278 (15600); λ_{max} [H₂O (pH 13)] unstable.
19. Selected spectral data for **9**: ms *m/z*: 165 (M⁺); uv λ_{max} [95% (v/v) aq. EtOH] 273 nm (ε 9400); λ_{max} [H₂O (pH 1)] 274 (13400); λ_{max} [H₂O (pH 7)] 271 (10200); λ_{max} [H₂O (pH 13)] 273 (10600); ¹H nmr (Me₂SO-*d*₆) δ: 4.13 (3H, s, OMe), 7.11 (2H, br, NH₂), 8.21 and 8.64 (1H each, s, purine protons).
20. T. Date and K. Okamura (Tanabe Seiyaku, Co., Ltd.), personal communication, June 1993.

Received, 20th October, 1993